Search
Zhixiang Jintai Receives Approval for Drug Clinical Trial
1 week ago /
Read about 0 minute
Author：小编
Zhixiang Jintai has announced that its in-house developed GR1803 injection, in combination with an anti-CD38 monoclonal antibody, has obtained approval from the National Medical Products Administration for clinical trials in adult patients diagnosed with relapsed/refractory multiple myeloma. This groundbreaking bispecific antibody drug will necessitate the submission of a new drug marketing authorization application upon the completion of its clinical trials.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
